AI English summary of an SEC filing — figures as filed
HCA Healthcare HCAThe company said revenues for Q2 2024 totaled $17.492 billion, net income attributable to the parent totaled $1.461 billion ($5.53 per diluted share), and Adjusted EBITDA totaled $3.550 billion. In the prior-year period, the figures were $15.861 billion, $1.193 billion and $3.056 billion, respectively.
Key points
AI summaryThe company said revenues for Q2 2024 totaled $17.492 billion, net income attributable to the parent totaled $1.461 billion ($5.53 per diluted share), and Adjusted EBITDA totaled $3.550 billion. In the prior-year period, the figures were $15.861 billion, $1.193 billion and $3.056 billion, respectively.
HCA said same facility admissions rose 5.8% in Q2 from a year earlier, and equivalent admissions rose 5.2%. Same facility emergency room visits increased 5.5%, while outpatient surgeries declined 2.1%.
The company said operating cash flow for Q2 was $1.971 billion, lower than $2.475 billion in the same period a year earlier. During the same quarter, it repurchased 4.217 million shares at a cost of $1.367 billion, and as of June 30, $4.228 billion remained under its repurchase authorization.
The company said it revised its full-year 2024 revenue outlook to $69.750 to $71.750 billion and its Adjusted EBITDA outlook to $13.750 to $14.250 billion. The prior outlook, as of January 30, was $67.750 to $70.250 billion for revenues and $12.850 to $13.550 billion for Adjusted EBITDA. It also declared a quarterly dividend of $0.66 per share.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q2 Revenue, Net Income and Adjusted EBITDA
The company said revenues for Q2 2024 totaled $17.492 billion, net income attributable to the parent totaled $1.461 billion ($5.53 per diluted share), and Adjusted EBITDA totaled $3.550 billion. In the prior-year period, the figures were $15.861 billion, $1.193 billion and $3.056 billion, respectively.
Source · Based on the filing body and exhibits
Same Facility Admissions, Emergency Room and Outpatient Surgery Metrics
HCA said same facility admissions rose 5.8% in Q2 from a year earlier, and equivalent admissions rose 5.2%. Same facility emergency room visits increased 5.5%, while outpatient surgeries declined 2.1%.
Source · Based on the filing body and exhibits
Cash Flow, Share Repurchases and Remaining Authorization
The company said operating cash flow for Q2 was $1.971 billion, lower than $2.475 billion in the same period a year earlier. During the same quarter, it repurchased 4.217 million shares at a cost of $1.367 billion, and as of June 30, $4.228 billion remained under its repurchase authorization.
Source · Based on the filing body and exhibits
Full-Year 2024 Outlook Revised and Dividend Declared
The company said it revised its full-year 2024 revenue outlook to $69.750 to $71.750 billion and its Adjusted EBITDA outlook to $13.750 to $14.250 billion. The prior outlook, as of January 30, was $67.750 to $70.250 billion for revenues and $12.850 to $13.550 billion for Adjusted EBITDA. It also declared a quarterly dividend of $0.66 per share.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…